Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Crooks

Showing results (281-290 of 319) with videos related to

Pageof 32
Sort By:
Molecular Cancer Therapeutics|June 2, 2007
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivoMichele T Yip-Schneider, Huangbing Wu, Matthew Ralstin, et al.
The Journal of Organic Chemistry|March 28, 2008
Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligandsBalwinder S Bhatti, Jon-Paul Strachan, Scott R Breining, et al.
European Journal of Medicinal Chemistry|August 14, 2014
Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progressionNarsimha R Penthala, Shobanbabu Bommagani, Venumadhav Janganati, et al.
Pharmacological Research|September 18, 2016
Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptorsJai Shankar K Yadlapalli, Benjamin M Ford, Amit Ketkar, et al.
European Journal of Pharmacology|March 5, 2011
Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine releaseMarharyta Pivavarchyk, Andrew M Smith, Zhenfa Zhang, et al.
Journal of Cellular and Molecular Medicine|August 7, 2018
Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen speciesGabriela Flores-Lopez, Dafne Moreno-Lorenzana, Manuel Ayala-Sanchez, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2010
Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporterWerner J Geldenhuys, Vamshi K Manda, Rajendar K Mittapalli, et al.
Frontiers in Toxicology|January 2, 2023
Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cellsFrancesca V LoBianco, Kimberly J Krager, Erica Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 2007
Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrierPaul R Lockman, Vamshi K Manda, Werner J Geldenhuys, et al.
Blood|October 5, 2010
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathwaysDuane C Hassane, Siddhartha Sen, Mohammad Minhajuddin, et al.
Pageof 32

Showing results (281-290 of 319) with videos related to

Sort By:
Pageof 32
Molecular Cancer Therapeutics|June 2, 2007
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivoMichele T Yip-Schneider, Huangbing Wu, Matthew Ralstin, et al.
The Journal of Organic Chemistry|March 28, 2008
Synthesis of 2-(pyridin-3-yl)-1-azabicyclo[3.2.2]nonane, 2-(pyridin-3-yl)-1-azabicyclo[2.2.2]octane, and 2-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, a class of potent nicotinic acetylcholine receptor-ligandsBalwinder S Bhatti, Jon-Paul Strachan, Scott R Breining, et al.
European Journal of Medicinal Chemistry|August 14, 2014
Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progressionNarsimha R Penthala, Shobanbabu Bommagani, Venumadhav Janganati, et al.
Pharmacological Research|September 18, 2016
Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptorsJai Shankar K Yadlapalli, Benjamin M Ford, Amit Ketkar, et al.
European Journal of Pharmacology|March 5, 2011
Indolizidine (-)-235B' and related structural analogs: discovery of nicotinic receptor antagonists that inhibit nicotine-evoked [3H]dopamine releaseMarharyta Pivavarchyk, Andrew M Smith, Zhenfa Zhang, et al.
Journal of Cellular and Molecular Medicine|August 7, 2018
Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen speciesGabriela Flores-Lopez, Dafne Moreno-Lorenzana, Manuel Ayala-Sanchez, et al.
Bioorganic & Medicinal Chemistry Letters|January 8, 2010
Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporterWerner J Geldenhuys, Vamshi K Manda, Rajendar K Mittapalli, et al.
Frontiers in Toxicology|January 2, 2023
Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cellsFrancesca V LoBianco, Kimberly J Krager, Erica Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 9, 2007
Carrier-mediated transport of the quaternary ammonium neuronal nicotinic receptor antagonist n,n'-dodecylbispicolinium dibromide at the blood-brain barrierPaul R Lockman, Vamshi K Manda, Werner J Geldenhuys, et al.
Blood|October 5, 2010
Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathwaysDuane C Hassane, Siddhartha Sen, Mohammad Minhajuddin, et al.
Pageof 32